N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo.

We reported previously that synthetic amides of polyunsaturated fatty acids with bioactive amines can result in substances that interact with proteins of the endogenous cannabinoid system (ECS). Here we synthesized a series of N-acyl-dopamines (NADAs) and studied their effects on the anandamide membrane transporter, the anandamide amidohydrolase (fatty acid amide hydrolase, FAAH) and the two cannabinoid receptor subtypes, CB(1) and CB(2). NADAs competitively inhibited FAAH from N18TG2 cells (IC(50)=19-100 microM), as well as the binding of the selective CB(1) receptor ligand, [(3)H]SR141716A, to rat brain membranes (K(i)=250-3900 nM). The arachidonoyl (20:4 omega 6), eicosapentaenoyl (20:5 omega 3), docosapentaenoyl (22:5 omega 3), alpha-linolenoyl (18:3 omega 3) and pinolenoyl (5c,9c,12c 18:3 omega 6) homologues were also found to inhibit the anandamide membrane transporter in RBL-2H3 basophilic leukaemia and C6 glioma cells (IC(50)=17.5-33 microM). NADAs did not inhibit the binding of the CB(1)/CB(2) receptor ligand, [(3)H]WIN55,212-2, to rat spleen membranes (K(i)>10 microM). N-arachidonyl-dopamine (AA-DA) exhibited 40-fold selectivity for CB(1) (K(i)=250 nM) over CB(2) receptors, and N-docosapentaenoyl-dopamine exhibited 4-fold selectivity for the anandamide transporter over FAAH. AA-DA (0.1-10 microM) did not displace D1 and D2 dopamine-receptor high-affinity ligands from rat brain membranes, thus suggesting that this compound has little affinity for these receptors. AA-DA was more potent and efficacious than anandamide as a CB(1) agonist, as assessed by measuring the stimulatory effect on intracellular Ca(2+) mobilization in undifferentiated N18TG2 neuroblastoma cells. This effect of AA-DA was counteracted by the CB(1) antagonist SR141716A. AA-DA behaved as a CB(1) agonist in vivo by inducing hypothermia, hypo-locomotion, catalepsy and analgesia in mice (1-10 mg/kg). Finally, AA-DA potently inhibited (IC(50)=0.25 microM) the proliferation of human breast MCF-7 cancer cells, thus behaving like other CB(1) agonists. Also this effect was counteracted by SR141716A but not by the D2 antagonist haloperidol. We conclude that NADAs, and AA-DA in particular, may be novel and useful probes for the study of the ECS.

[1]  C. Hillard,et al.  The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. , 2000, Chemistry and physics of lipids.

[2]  J. Brotchie,et al.  Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  P. Zygmunt,et al.  The anandamide transport inhibitor AM404 activates vanilloid receptors. , 2000, European journal of pharmacology.

[4]  A. Finazzi-Agro’,et al.  Anandamide Uptake by Human Endothelial Cells and Its Regulation by Nitric Oxide* , 2000, The Journal of Biological Chemistry.

[5]  D. Smart,et al.  Anandamide: an endogenous activator of the vanilloid receptor. , 2000, Trends in pharmacological sciences.

[6]  S. Yamamoto,et al.  Anandamide amidohydrolase (fatty acid amide hydrolase). , 2000, Prostaglandins & other lipid mediators.

[7]  R. Blakely,et al.  Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. , 2000, The Journal of pharmacology and experimental therapeutics.

[8]  I. Galve-Roperh,et al.  Involvement of the cAMP/protein kinase A pathway and of mitogen‐activated protein kinase in the anti‐proliferative effects of anandamide in human breast cancer cells , 1999, FEBS letters.

[9]  T. Bisogno,et al.  Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. , 1999, Biochemical and biophysical research communications.

[10]  L. Petrocellis,et al.  Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. , 1999, Current medicinal chemistry.

[11]  S. Yamamoto,et al.  An acid amidase hydrolyzing anandamide as an endogenous ligand for cannabinoid receptors , 1999, FEBS letters.

[12]  R. Mechoulam,et al.  Discovery and characterization of endogenous cannabinoids. , 1999, Life sciences.

[13]  W. Campbell,et al.  Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). , 1999, The Journal of pharmacology and experimental therapeutics.

[14]  I. Yamamoto,et al.  Pharmacological effects in mice of anandamide and its related fatty acid ethanolamides, and enhancement of cataleptogenic effect of anandamide by phenylmethylsulfonyl fluoride. , 1999, Biological & pharmaceutical bulletin.

[15]  W. Graier,et al.  Anandamide‐induced mobilization of cytosolic Ca2+ in endothelial cells , 1999, British journal of pharmacology.

[16]  L. Parsons,et al.  Dopamine activation of endogenous cannabinoid signaling in dorsal striatum , 1999, Nature Neuroscience.

[17]  K. Abouzid,et al.  Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. , 1999, Journal of medicinal chemistry.

[18]  D. Deutsch,et al.  Biochemistry of the Endogenous Ligands of Cannabinoid Receptors , 1998, Neurobiology of Disease.

[19]  T. Bisogno,et al.  Interactions between synthetic vanilloids and the endogenous cannabinoid system , 1998, FEBS letters.

[20]  A. Basbaum,et al.  The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli , 1998, Neuron.

[21]  L. Petrocellis,et al.  Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. , 1998, Biochemical and biophysical research communications.

[22]  L. Petrocellis,et al.  The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  L. Petrocellis,et al.  Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells--implications for cell proliferation and differentiation. , 1998, European journal of biochemistry.

[24]  V. Marzo ‘Endocannabinoids’ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance , 1998 .

[25]  W. Campbell,et al.  Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid. , 1997, Journal of lipid research.

[26]  I. Yamamoto,et al.  Is the cannabinoid CB1 receptor a 2-arachidonoylglycerol receptor? Structural requirements for triggering a Ca2+ transient in NG108-15 cells. , 1997, Journal of biochemistry.

[27]  Z. Vogel,et al.  Anandamide may mediate sleep induction , 1997, Nature.

[28]  W. Campbell,et al.  Accumulation of N‐Arachidonoylethanolamine (Anandamide) into Cerebellar Granule Cells Occurs via Facilitated Diffusion , 1997, Journal of neurochemistry.

[29]  V. Makarov,et al.  [Artificially functionalized polyenoic fatty acids--a new lipid bioregulators]. , 1997, Bioorganicheskaia khimiia.

[30]  T. Bisogno,et al.  Biosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in Leukocytes* , 1997, The Journal of Biological Chemistry.

[31]  V. Showalter,et al.  Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells. , 1997, Biochemical pharmacology.

[32]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[33]  T. Bisogno,et al.  Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma ‘anandamide amidohydrolase’ , 1995, FEBS letters.

[34]  N. Ueda,et al.  Partial Purification and Characterization of the Porcine Brain Enzyme Hydrolyzing and Synthesizing Anandamide (*) , 1995, The Journal of Biological Chemistry.

[35]  A. Yamashita,et al.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.

[36]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[37]  D. Johnson,et al.  The growth inhibitory properties of a dopamine agonist (SKF 38393) on MCF-7 cells. , 1995, Anti-cancer drugs.

[38]  J. Schwartz,et al.  Formation and inactivation of endogenous cannabinoid anandamide in central neurons , 1994, Nature.

[39]  S. Bevan,et al.  Characterization of resiniferatoxin binding sites on sensory neurons: Co-regulation of resiniferatoxin binding and capsaicin sensitivity in adult rat dorsal root ganglia , 1993, Neuroscience.

[40]  J. Crawley,et al.  Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents , 1993, Pharmacology Biochemistry and Behavior.

[41]  T R LaHann,et al.  Vanilloids. 1. Analogs of capsaicin with antinociceptive and antiinflammatory activity. , 1993, Journal of medicinal chemistry.

[42]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[43]  S. Bevan,et al.  Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 2. The amide bond "B-region". , 1993, Journal of medicinal chemistry.

[44]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[45]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[46]  M. Martres,et al.  Presence of dopamine D-2 receptors in human tumoral cell lines. , 1989, Biochemical and biophysical research communications.

[47]  R. Pertwee The ring test: a quantitative method for assessing the ‘cataleptic’ effect of cannabis in mice , 1972, British journal of pharmacology.

[48]  Bobrov MYu,et al.  Bioactive amides of fatty acids. , 1998, Biochemistry. Biokhimiia.

[49]  V. Di Marzo 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. , 1998, Biochimica et biophysica acta.

[50]  R. Pertwee Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[51]  V. Di Marzo,et al.  Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. , 2000, Endocrinology.